A recent study published in the Journal of Thrombosis and Haemostasis has found that exposure to long-wavelength red light may reduce clotting risk in both mice and humans. Conducted by researchers at the University of Pittsburgh, the study used a 72-hour light-dark cycle to expose wild-type C57BL/6J mice to ambient white light, blue light, or red light, with the aim of investigating its impact on platelet function.
The findings showed that exposure to long-wavelength red light resulted in reduced platelet aggregation and activation, as well as decreased thrombosis-generating neutrophil extracellular trap formation. The researchers also found that mice exposed to red light had improved outcomes in murine models of venous thromboembolism and stroke.
In humans, the study used a similar approach by evaluating the rate of venous thromboembolism in patients with cataract lenses that filter low-wavelength light over an 8-year period. The results showed that these patients had a lower lifetime risk of venous thromboembolism compared to those without such lenses.
The researchers believe that their findings suggest that light therapy may be a promising approach for thrombus prophylaxis by targeting the intersection between innate immune function and coagulation. However, further research is needed to fully understand the effects of red light on human platelet function and its potential applications in preventing or treating blood clots.
As a result of this study, the researchers are now developing red light goggles to control the amount of light exposure for future clinical trials. This innovative approach aims to provide patients with a more convenient and potent treatment option for reducing clotting risk.
Source: https://neurosciencenews.com/red-light-therapy-blood-clots-28350